Apoptotic Enterocolitis

Slide 1 · Apoptotic Enterocolitis

Mucosal injury patterns, clinical contexts and biopsy interpretation

An integrated approach to crypt apoptosis, drug injury and GVHD

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Identify excess epithelial apoptosis in intestinal biopsies.

Explain why crypt injury produces epithelial loss and diarrhea.

Distinguish checkpoint-inhibitor toxicity, mycophenolate injury and gastrointestinal GVHD.

Use clinical context and ancillary testing to avoid false etiologic attribution.

Slide 3 · A reaction pattern—not one etiologic disease

“Apoptotic enterocolitis” describes increased programmed epithelial cell death in gastrointestinal mucosa.

Different injuries can converge on a similar microscopic phenotype.

Histology establishes the pattern; Medication and transplant history often establish the cause.

Interpret apoptosis as a finding requiring etiologic correlation.

Slide 4 · Core etiologic contexts

Immune checkpoint inhibitors

Oncologic therapy; Immune-mediated mucosal injury

Mycophenolate mofetil

Immunosuppressive drug-associated epithelial injury

Allogeneic HSCT / GVHD

Donor-derived T-cell injury of recipient crypts

Overlapping morphology ≠ interchangeable diagnoses.

Slide 5 · Why the heading matters in practice

Diarrhea in cancer or transplant care has multiple potential explanations.

Mucosal apoptosis can be subtle despite clinically important symptoms.

An incorrect label may alter oncology or immunosuppression decisions.

Slide 6 · Normal intestinal crypt architecture

Schematic: Crypt epithelial response

Crypt 1

Crypt 2

Crypt 3

Read the schematic

Blue epithelium — Surrounds a pale glandular lumen

Dark small nuclei — Illustrate epithelial cells

Three crypts — Show the normal repeated architecture

The epithelial renewal compartment is concentrated in the crypts.

Original schematic — not a histologic specimen

Slide 7 · Physiologic renewal versus pathologic apoptosis

Physiologic turnover

Epithelial cell production and shedding remain balanced

Architectural integrity is maintained

Pathologic apoptotic injury

Increased epithelial loss overwhelms local replacement

Crypt attenuation, loss and mucosal dysfunction may follow

Slide 8 · What an apoptotic body represents

An epithelial cell undergoing programmed death forms a condensed, fragmented remnant.

Apoptotic debris may be present within or adjacent to crypt epithelium.

The distribution and associated injuries are more useful than an isolated body.

Slide 9 · Apoptosis is distinct from necrosis

Feature

Apoptosis

Necrosis

Cell response

Single-cell shrinkage / fragmentation

Cell swelling and membrane breakdown

Tissue response

May occur with limited inflammation

Often provokes adjacent inflammation

Biopsy clue

Discrete epithelial apoptotic bodies

Confluent cell / tissue injury

Slide 10 · The pathologist asks four separate questions

Is apoptosis increased?

Where is injury centered?

What other patterns coexist?

Which exposure / disease fits?

Causal / diagnostic sequence (simplified)

The etiologic diagnosis is the final step, not the first.

Slide 11 · Crypt-centered injury can be clinically important

Schematic: Crypt epithelial response

Intact crypt

Crypt apoptosis

More apoptosis

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Scattered apoptotic cells may signal damage to the crypt renewal compartment.

Original schematic — not a histologic specimen

Slide 12 · Severe injury progresses to crypt dropout

Schematic: Crypt epithelial response

Intact crypt

Apoptotic injury

Crypt dropout

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Loss of crypts indicates more extensive epithelial destruction.

Original schematic — not a histologic specimen

Slide 13 · A useful injury continuum

Scattered epithelial apoptosis

Damaged / atrophic crypts

Crypt loss and epithelial deficit

Impaired mucosal function

Causal / diagnostic sequence (simplified)

A schematic continuum—not a mandatory sequence in every patient.

Slide 14 · Why diarrhea accompanies epithelial injury

Intact intestinal epithelium is needed for fluid handling and barrier function.

Inflammatory injury or epithelial loss can disrupt transport and absorption.

Diarrhea alone does not establish the mechanism or culprit drug.

Clinical severity and apoptotic-body density need not map one-to-one.

Slide 15 · Clinical history is part of the biopsy

Clinical question

Why it changes interpretation

Checkpoint blockade?

Supports an immune-related treatment injury pattern

Mycophenolate exposure?

Supports a recognized drug-associated apoptotic colonopathy

Allogeneic stem-cell transplant?

Introduces gastrointestinal GVHD into the differential

Infection work-up?

Infections can coexist or mimic mucosal injury

Slide 16 · Checkpoint inhibitors: The clinical setting

Immune checkpoint inhibitors are used in oncology to augment antitumor immune responses.

Enterocolitis and diarrhea are important treatment-related toxicities.

Severe toxicity can necessitate discontinuation of treatment.

Slide 17 · Checkpoint blockade and off-target intestinal injury

Immune checkpoint blockade

Reduced inhibitory immune signaling

Intestinal immune dysregulation

Mucosal epithelial injury

Causal / diagnostic sequence (simplified)

Mechanisms are multifactorial; The source does not specify a single required pathway.

Slide 18 · Why checkpoint colitis resembles GVHD

Both settings can produce apoptosis of intestinal epithelial cells.

Partial mechanistic overlap as plausible but incompletely established.

Shared morphology does not imply the same initiating immune event.

Mechanistic analogy is not proof of mechanistic identity.

Slide 19 · Checkpoint colitis has more than one histologic pattern

Active colitis

Cryptitis, crypt abscesses ± apoptosis

Apoptosis / crypt injury

Apoptotic bodies with attenuation or dropout

Other inflammatory patterns

Chronic-active and microscopic-colitis-like changes

The full biopsy may not look purely “GVHD-like”.

Slide 20 · Active colitis pattern under checkpoint therapy

Neutrophils may invade crypt epithelium (cryptitis).

Crypt lumina can contain neutrophils (crypt abscesses).

Prominent epithelial apoptosis may coexist and suggest drug-related injury.

Slide 21 · An apoptosis-predominant checkpoint biopsy

Schematic: Crypt epithelial response

Intact crypt

Crypt apoptosis

More apoptosis

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Predominant apoptosis may occur without conspicuous architectural chronicity.

Original schematic — not a histologic specimen

Slide 22 · Crypt atrophy and dropout in checkpoint colitis

Atrophic crypts show attenuated epithelial lining.

Lumina may contain apoptotic debris mixed with inflammatory cells.

Crypt loss reflects more severe mucosal epithelial injury.

Slide 23 · Checkpoint injury may imitate chronic colitis

Architectural change and chronic inflammatory patterns can occur.

Persistent or prominent chronicity requires consideration of pre-existing or unmasked IBD.

Morphologic attribution depends on the chronology and earlier biopsies if available.

Slide 24 · Microscopic-colitis-like patterns also occur

Lymphocytic-like

Intraepithelial lymphocytes and superficial epithelial injury

Consider symptoms and checkpoint exposure

Collagenous-like

Thickened subepithelial collagen with inflammation

Do not force all ICI injury into an apoptotic-only pattern

Slide 25 · Endoscopic appearance does not define the histology

Checkpoint-associated colitis may show erythema, erosions, ulceration or a less striking surface appearance.

A biopsy evaluates mucosal inflammation, apoptosis and microscopic-pattern injury.

Normal-appearing mucosa does not always exclude pathologic microscopic findings.

Slide 26 · Diarrhea after checkpoint therapy: Differential

Possibility

Evidence to seek

Immune-mediated drug toxicity

Temporal association, compatible biopsy, exclusion of mimics

Infection

Appropriate stool / tissue studies and immune status

Inflammatory bowel disease

Prior history or sustained features of chronicity

Other drugs / treatment effects

Full medication and treatment timeline

Slide 27 · The clinical cost of attribution error

Patient with diarrhea

Assume treatment toxicity too early

Miss infection or alternate cause

Incorrect clinical decision

Causal / diagnostic sequence (simplified)

Biopsy interpretation should explicitly address credible mimics.

Slide 28 · Reporting checkpoint-associated mucosal injury

Describe the predominant pattern rather than asserting a unique microscopic hallmark.

Mention elevated crypt apoptosis, active colitis, dropout or chronicity when present.

Use qualified language: Findings can be compatible with checkpoint-related injury in context.

Slide 29 · Mycophenolate: A second major cause

Mycophenolate mofetil is an immunosuppressive therapy with recognized gastrointestinal adverse effects.

Robbins explicitly associates it with apoptotic enteritis and colitis.

The pattern can occur in patients already at risk of transplant-related infection.

Slide 30 · Mycophenolate and epithelial renewal

Mycophenolic acid exposure

Inhibition of purine synthesis (IMPDH)

Impaired renewal in susceptible mucosa

Crypt damage and epithelial apoptosis

Causal / diagnostic sequence (simplified)

Mechanistic context from external literature; The association, not this biochemical sequence.

Slide 31 · A mixed-pattern injury is typical of mycophenolate

Crypt apoptosis may coexist with distortion, focal active inflammation or isolated crypt damage.

An IBD-like or a GVHD-like morphology can dominate different biopsies.

The mixed pattern is a useful clue, but is not diagnostic in isolation.

Slide 32 · Morphology: Apoptosis plus crypt disarray

Schematic: Crypt epithelial response

Intact crypt

Apoptotic injury

Mixed injury

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Concurrent apoptotic bodies and altered crypt architecture suggest a drug-injury pattern.

Original schematic — not a histologic specimen

Slide 33 · Mycophenolate injury can mimic IBD

Crypt distortion and inflammatory activity may resemble inflammatory bowel disease.

Increased crypt epithelial apoptosis favors a drug-associated process in the proper setting.

IBD should not be diagnosed solely from architecture without assessing drug history.

Slide 34 · Mycophenolate injury can mimic GVHD

Both may show prominent epithelial apoptosis and crypt damage.

The clinical transplant type and concurrent medicines are critical.

After allogeneic HSCT, dual exposures can make a single-cause interpretation unreliable.

Slide 35 · Histologic details worth actively seeking

Feature

Interpretive relevance

Damaged / dilated crypts

Supports focal epithelial drug injury when other causes are excluded

Architectural distortion

Can mimic chronic IBD; not specific

Increased crypt apoptosis

Central injury feature, shared by GVHD and checkpoint colitis

Eosinophils / reactive changes

May coexist; no single ancillary clue is definitive

Slide 36 · Endoscopy in mycophenolate injury

The mucosa can be erythematous, eroded, ulcerated or deceptively unremarkable.

Changes may be patchy and are not inherently specific for a drug.

Multiple biopsy sites can document the distribution and coexistent lesions.

Slide 37 · A drug list can outweigh an isolated microfeature

Record exact drugs

Align exposure and symptom onset

Review biopsy injury pattern

Assess alternatives / dual pathology

Causal / diagnostic sequence (simplified)

“Drug-induced” is a clinicopathologic conclusion.

Slide 38 · Mycophenolate injury versus idiopathic IBD

Observation

Mycophenolate-associated

Idiopathic IBD

Crypt apoptosis

Often conspicuous

May occur, usually less defining

Crypt distortion

May be present

May be prominent in established disease

Clinical support

Exposure and exclusion of mimics

Compatible longitudinal history

Conclusion

Neither column alone is diagnostic

Integrate clinical course

Slide 39 · A key pitfall: Dual pathology

A patient taking mycophenolate can simultaneously acquire infectious colitis.

In transplant populations, immune injury, infection and drug toxicity may overlap.

Do not stop the search after recognizing apoptosis.

One biopsy can contain more than one pathologic process.

Slide 40 · Gastrointestinal GVHD: The reference comparator

Occurs after allogeneic hematopoietic stem-cell transplantation.

Donor T cells target recipient gastrointestinal epithelium.

Small intestine and colon are frequently involved.

Slide 41 · GVHD has a distinct initiating mechanism

Allogeneic stem-cell transplant

Donor T-cell recognition

Recipient crypt epithelial injury

Apoptosis ± crypt destruction

Causal / diagnostic sequence (simplified)

This initiating context differs from checkpoint drug blockade.

Slide 42 · Crypt apoptosis is central in gastrointestinal GVHD

Schematic: Crypt epithelial response

Intact crypt

Crypt apoptosis

More apoptosis

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Epithelial apoptosis, particularly of crypt cells, is the commonest histologic finding in the Robbins section.

Original schematic — not a histologic specimen

Slide 43 · Severe GVHD can eliminate crypts

Schematic: Crypt epithelial response

Intact crypt

Apoptotic injury

Crypt dropout

Read the schematic

Blue epithelium — Preserved / altered crypt lining

Red fragments — Schematic epithelial apoptosis

Broken gland — Represents severe crypt dropout

Complete crypt destruction is possible in severe intestinal GVHD.

Original schematic — not a histologic specimen

Slide 44 · Sparse inflammation does not exclude immune injury

That the lamina propria lymphocytic infiltrate is often sparse.

Prominent crypt epithelial damage can therefore outweigh the inflammatory-cell density.

Interpret the epithelial compartment independently from the stroma.

A low-cellularity lamina propria can accompany substantial crypt injury.

Slide 45 · The GVHD clinical phenotype

Intestinal GVHD often causes watery diarrhea.

With severe damage, diarrhea may become bloody.

Clinical transplant timing, medications and infections remain essential to interpretation.

Slide 46 · GVHD versus checkpoint injury

Feature

Gastrointestinal GVHD

Checkpoint-related enterocolitis

Typical context

Allogeneic HSCT

Cancer immunotherapy

Initiating context

Donor T-cell response

Immune checkpoint blockade

Common overlap

Crypt apoptosis / dropout

Crypt apoptosis / dropout

Additional patterns

Variable injury / mimics

Active or microscopic-colitis-like changes

Slide 47 · GVHD versus mycophenolate injury

Feature

GVHD

Mycophenolate-associated

Clinical clue

Allogeneic HSCT

Current or prior mycophenolate exposure

Microscopic overlap

Apoptosis and crypt loss

Apoptosis and crypt damage

Other clues

Often sparse lamina propria cells

May show mixed IBD-like morphology

Diagnostic principle

Exclude treatment / infection mimics

Drug attribution needs clinical support

Slide 48 · A three-way etiologic comparison

Question

Checkpoint toxicity

Mycophenolate

GVHD

Usual exposure

ICI therapy

Mycophenolate

Allogeneic HSCT

Shared signal

Epithelial apoptosis

Epithelial apoptosis

Crypt apoptosis

Common companion

Active colitis

Mixed / IBD-like changes

Crypt attenuation / dropout

Major constraint

Exclude infection

Exclude other injury

Exclude drug / infection mimics

Slide 49 · Infection belongs in every differential

Immunosuppressed patients can develop opportunistic gastrointestinal infection.

Infectious injury and apoptosis-associated processes can coexist.

Histology and appropriately directed ancillary studies complement clinical microbiology.

Slide 50 · CMV and other mimics: When to investigate

Consider viral infection particularly in transplant or immunosuppressed patients.

Evaluate suspicious cytopathic change and the clinical laboratory picture.

CMV immunohistochemistry is an ancillary test when warranted, not a replacement for tissue review.

Slide 51 · Why histology alone is insufficient

One H&E finding: Apoptosis

Several possible etiologies

Overlapping patterns / therapies

Correlate symptoms, exposure and tests

Causal / diagnostic sequence (simplified)

Reject the shortcut “apoptosis = GVHD”.

Slide 52 · Low-power biopsy assessment

Assess specimen adequacy and site before interpreting focal crypt abnormalities.

Scan overall crypt density, architecture and inflammation.

Look for erosions or ulceration that could alter the biopsy context.

Slide 53 · Intermediate-power crypt assessment

Identify crypt attenuation, dilatation, damage and dropout.

Note whether abnormalities are diffuse or patchy across the sample.

Compare crypt injury with the density and distribution of inflammation.

Slide 54 · High-power assessment of epithelial apoptosis

Locate apoptotic bodies within the epithelium rather than luminal detritus alone.

Assess their frequency across multiple well-oriented crypts.

Avoid asserting a universal numerical cutoff: Thresholds vary by setting and publication.

Slide 55 · Assess companion findings separately

Companion finding

Question raised

Neutrophilic cryptitis / abscess

Is there an active inflammatory component?

Basal inflammation / distortion

Is there substantial chronic mucosal injury?

Crypt dropout / attenuation

How extensive is epithelial injury?

Viral cytopathy / ulceration

Is a second injury process present?

Slide 56 · A structured pathology sign-out

Identify sampled site

Describe pattern + severity

List salient negative / positive features

Correlate with therapies and tests

Causal / diagnostic sequence (simplified)

Report the observed morphology before the favored etiology.

Slide 57 · Suggested descriptive biopsy wording

“Colonic mucosa with increased crypt epithelial apoptosis and focal crypt injury.”

Add observed associated active colitis, architecture change or dropout as appropriate.

“Findings are compatible with treatment-related injury in the correct clinical setting; Clinical correlation is required.”

Slide 58 · The most common interpretation traps

One finding, one disease

Do not equate crypt apoptosis with GVHD alone

Morphology without timeline

Different therapies may yield overlapping injury

Missing co-pathology

Infection and drug injury can coexist

Slide 59 · Case 1: Diarrhea during cancer immunotherapy

Illustrative scenario: An oncology patient develops watery diarrhea while receiving checkpoint blockade.

Biopsy shows active cryptitis plus increased epithelial apoptosis.

Question: Which alternative diagnoses must be considered before attributing all injury to the drug?

Teaching answer (shown for discussion): Infection, pre-existing or unmasked IBD, and other treatment or drug effects; Integrate stool studies, medications and biopsy.

Slide 60 · Case 2: Diarrhea in a solid-organ recipient

Illustrative scenario: A renal-transplant patient takes mycophenolate and develops persistent diarrhea.

Biopsy shows crypt apoptosis, focal distortion and isolated damaged crypts.

Question: Why is a primary IBD label premature?

Teaching answer (shown for discussion): Mycophenolate can produce an IBD-like injury pattern; Exposure, infections and clinical evolution must be assessed.

Slide 61 · Case 3: Diarrhea after allogeneic HSCT

Illustrative scenario: A stem-cell recipient develops profuse watery diarrhea.

Biopsy shows crypt cell apoptosis and some crypt loss, with sparse lamina propria lymphocytes.

Question: What is favored and what confounders remain?

Teaching answer (shown for discussion): GI GVHD is a key consideration; Concurrent drugs, infections and timing can complicate attribution.

Slide 62 · Integrated work-up: From biopsy pattern to cause

Recognize apoptotic crypt injury

Map treatment and transplant history

Seek inflammation / infection clues

Give qualified integrated diagnosis

Causal / diagnostic sequence (simplified)

No etiologic decision is made from apoptotic bodies alone.

Slide 63 · What each major clue can—and cannot—tell you

Clue

Supports

Does NOT prove

Increased apoptosis

Apoptotic-type injury

A specific etiologic category

Checkpoint exposure

Possible immune-related colitis

Exclusion of infectious colitis

Mycophenolate exposure

Possible drug toxicity

Absence of GVHD / infection

Allogeneic transplant

GVHD risk

Every crypt lesion is GVHD

Slide 64 · Five principles to retain

Apoptotic enterocolitis is a convergent epithelial injury pattern.

Checkpoint therapy, mycophenolate and GVHD are core clinical settings.

Crypt apoptosis can coexist with active inflammation, architectural distortion or dropout.

The clinical timeline and infection assessment are indispensable.

Biopsy reports should describe what is seen and qualify causal attribution.

Slide 65 · Selected references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026; Chapter 17, p. 734.

Sun et al. Immune checkpoint inhibitor–related colitis. Am J Clin Pathol. 2024. PMID: 38377034.

Liapis et al. Histological spectrum of mycophenolate mofetil–related colitis. Histopathology. 2013. doi:10.1111/his.12222.

Zhang & Hagen. GI biopsies post-stem cell transplant: approach to diagnosis. Surg Pathol Clin. 2023. PMID: 37863563.

ECCO Topical Review on the clinicopathological spectrum and differential diagnosis of IBD. J Crohns Colitis. 2022.

Apoptotic colonopathy under immunosuppression: mycophenolate-related effects and beyond. PMID: 24013803.